Hearing Loss and Dementia Risk: The Longevity Factor Nobody Screens For

Here's how it usually starts. Somebody is sitting across from me and mentions, almost as an aside, that restaurants have gotten too loud. They went out to dinner at Southlake Town Square on a Friday night, the place was packed, and they spent the whole meal nodding along to a conversation they caught maybe half of. They're not worried about it. They figure the restaurant is the problem.

Sometimes the restaurant really is the problem. Often it isn't.

I'm Dr. Farhan Abdullah, an internal medicine physician and the Medical Director at Magnolia Functional Wellness in Southlake. I still round in a Dallas hospital most weeks, which means I spend a fair amount of time with older adults at the point where things have already gone sideways. And of everything we discuss under the heading of longevity, the risk factor that gets the least attention relative to the evidence behind it isn't a supplement, a fasting window, or a cold plunge. It's hearing.

That sounds underwhelming. Stay with me, because the data here is more interesting, and more honest, than the headlines suggest.

The Observation That Started All of This

The modern version of this story begins with a 2011 paper in Archives of Neurology from Frank Lin and colleagues at Johns Hopkins, working with data from the Baltimore Longitudinal Study of Aging (Lin et al., Arch Neurol 2011). They had something unusual: formal audiometry performed on 639 adults back in the early 1990s, and then more than a decade of follow-up watching who developed dementia.

The pattern was hard to ignore. Compared with people who had normal hearing at baseline, the risk of developing dementia was roughly doubled in those with mild hearing loss, tripled with moderate loss, and close to five times higher with severe loss. It scaled with severity, which is the kind of dose-response relationship that makes epidemiologists sit up straight. Random noise doesn't usually line up that neatly.

Now, an observational study can't tell you which direction the arrow points. Maybe hearing loss contributes to dementia. Maybe the earliest neurodegenerative changes affect how the brain processes sound, so the hearing loss is a symptom rather than a cause. Maybe some third thing, vascular disease being the obvious candidate, damages the cochlea and the brain in parallel. All three are plausible, and for years that ambiguity was where the conversation stalled.

Why the Lancet Commission Put Hearing Near the Top

What moved hearing from interesting-footnote to front-page is the Lancet standing Commission on dementia prevention. Their 2024 report (Livingston et al., Lancet 2024) identified fourteen modifiable risk factors and estimated that, in theory, eliminating all of them would prevent or delay about 45 percent of dementia cases worldwide.

Forty-five percent. That number deserves a moment. We spend enormous energy searching for a drug that moves dementia risk a few percentage points, and here's a commission of serious people saying that close to half the burden traces back to things that are, at least in principle, changeable. Blood pressure. Diabetes. Physical inactivity. Smoking. Obesity. Social isolation. Depression. Education. Air pollution. Head injury. Vision loss. Cholesterol.

And hearing loss in midlife, which the Commission has consistently ranked at or near the top of the individual factors. Not because hearing loss is the most dangerous thing on the list, but because it's extremely common and almost nobody treats it. A risk factor's population impact is severity multiplied by prevalence, and untreated hearing loss scores high on prevalence in a way that, say, traumatic brain injury does not.

Here's the part I find genuinely frustrating as a physician. We screen relentlessly for the metabolic items on that list. Every patient who walks into my office gets blood pressure, glucose, and a lipid panel without anyone thinking twice. Hearing sits on the same list, and it gets screened almost never. The average person waits years between noticing a problem and doing anything about it, and by then they've usually rearranged their life around it.

Then ACHIEVE Happened, and the Story Got Complicated

This is where I have to be straight with you, because a lot of wellness content on this topic stops before it gets here.

In 2023, the ACHIEVE trial was published in The Lancet (Lin et al., Lancet 2023). This was the randomized controlled trial the field had been waiting on for a decade. Researchers enrolled 977 adults between 70 and 84 with untreated hearing loss, randomly assigned half to a best-practice hearing intervention with audiologist-fitted hearing aids and half to a health education control, and followed global cognition for three years.

The headline result was null. Across the full study population, three-year cognitive change was essentially identical between the two groups. If you were hoping for a clean "hearing aids prevent cognitive decline" verdict, ACHIEVE did not deliver one.

But the trial had a design feature that turned out to matter enormously. It recruited from two different populations. About three quarters were healthy volunteers recruited de novo, and roughly a quarter came from the ARIC study, a long-running cardiovascular cohort whose participants were older, had more risk factors, and were declining faster to begin with. In that ARIC group, the ones actually at elevated risk, the hearing intervention cut three-year cognitive decline by roughly half.

How you read that depends on your temperament. A skeptic says it's a subgroup finding and subgroups lie to you all the time. A more generous reading is that the healthy-volunteer group barely declined at all over three years, so there was almost no decline available to prevent. You can't slow a car that isn't moving. The ARIC participants were on a trajectory, and the intervention appeared to bend it.

My own read, and I'll own that this is judgment rather than proof, is that the second interpretation is more likely correct. But I tell patients plainly that the definitive trial has not been run. What we have is a null primary outcome with a striking signal in exactly the group where you'd expect to find one.

What Happens When People Actually Treat It

Outside the trial setting, the observational evidence on hearing devices is reasonably consistent. A systematic review and meta-analysis in JAMA Neurology pooled data from studies covering more than 126,000 participants and found that use of hearing aids or cochlear implants was associated with roughly a 19 percent lower hazard of long-term cognitive decline (Yeo et al., JAMA Neurol 2023).

Observational again, with all the usual caveats. People who buy and consistently wear hearing aids differ from people who don't in a dozen ways that are hard to measure. They tend to have more money, more engagement with the medical system, and more social motivation to hear well. Any of those could drive the association on its own.

Still. When the longitudinal cohorts, the meta-analyses, and the at-risk arm of the randomized trial all point the same direction, I stop treating it as noise.

Why Hearing Would Affect the Brain at All

Association is more persuasive when there's a mechanism, and there are three credible ones. They aren't mutually exclusive, which is probably the point.

The first is cognitive load. When the signal reaching your auditory cortex is degraded, your brain compensates by throwing more resources at decoding it. Listening stops being automatic and becomes work. Those resources get pulled from somewhere, usually working memory, which is why people with untreated hearing loss often describe difficulty following a conversation rather than difficulty hearing it. That's also why the exhaustion is real. Patients tell me they come home from a dinner party wiped out, and they assume they're getting old. They're not tired from socializing. They're tired from translating.

The second is social withdrawal, and this is the one I watch for most closely. It happens gradually and almost nobody narrates it out loud. You skip the loud restaurant. You stop calling the friend whose voice is hard to catch on the phone. You sit out of the group conversation because asking people to repeat themselves three times feels humiliating. Within a couple of years you've quietly built a much smaller life, and social isolation is itself an independent risk factor on the Commission's list. Hearing loss doesn't just sit next to isolation on that list. It feeds it.

The third is structural. Imaging work has shown accelerated atrophy in the temporal regions of adults with hearing loss, which fits the general principle that neural tissue deprived of its normal input doesn't hold up well. Use it or lose it isn't just a slogan for muscle.

How I Handle This at Magnolia

Practically, this has changed how I take a history. I ask directly rather than waiting for someone to bring it up, because almost nobody brings it up. Do you struggle in restaurants? Has anyone complained about the television volume? Do you find yourself avoiding phone calls? Do you catch yourself watching people's mouths? Those questions surface far more than "how's your hearing," which reliably gets a "fine."

If the answers point somewhere, I refer for formal audiometry. Not an app, not a whispered-voice test in the exam room. Real audiometry, so we have a baseline number to compare against in five years. And I'd rather get that baseline while hearing is still normal, for the same reason we don't wait for chest pain to check a lipid panel.

I also want to be clear about what hearing is and isn't in this picture. It's one item on a list of fourteen, and the metabolic entries on that list are the ones I spend most of my time on. Blood pressure, insulin resistance, visceral fat, lipids, and physical activity are the bulk of the work in our longevity medicine program, and for good reason. Several of those factors are also what drives sustained weight loss under real physician supervision, which our guide to physician-supervised GLP-1 weight loss walks through in detail. Hearing doesn't replace any of that. It belongs alongside it.

What makes hearing unusual is the cost-to-benefit ratio. Most of what we do in preventive medicine asks for sustained behavior change over years. Hearing correction asks you to go to one appointment, then wear a device. Over-the-counter hearing aids have been available in the United States since 2022, which knocked out the price barrier that kept a lot of people away. The remaining barrier is almost entirely vanity, and I say that with sympathy rather than judgment. Nobody wants to be the person with the hearing aid. But I'd point out that nobody blinks at reading glasses, and the mechanism there is identical: a sensory organ wore out, and we built a device for it.

The Part Worth Remembering

I'm not going to tell you hearing aids prevent dementia. The randomized evidence doesn't support that claim, and anyone making it flatly is going past what we know.

What I'll say is this. Untreated hearing loss is common, it's cheap to identify, it sits on the shortest list of modifiable dementia risk factors we have, and the trial evidence suggests real benefit in exactly the people who are already at risk. Meanwhile the downstream effects on social connection and daily fatigue are certain, immediate, and don't require you to believe anything about dementia at all. Even if the cognitive story eventually turns out to be weaker than we hope, you still get to hear your grandkids at Thanksgiving.

So if you've been telling yourself the restaurants got louder, get the hearing test. If you're over 60 and have never had audiometry, get a baseline. And bring it up at your next visit, because it belongs in the same conversation as your blood pressure and your labs. That's how we treat it here in Southlake, and it's one of the few interventions in this field where the math is genuinely in your favor.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX